Tuojie Pharmaceutical Completes Nearly $40 Million Series A Financing, Total Investment Approaches $100 Million

Tuojie Pharmaceutical has completed nearly $40 million in Series A financing. This round of financing was jointly led by Yuanhe Origin and Decheng Capital, with participation from Longpan Investment, Jifeng Capital, Mifang Health Fund, Songqing Capital, and Jianfa Emerging Investment. Dianshi Capital acted as the exclusive financial advisor. The funds will be used to accelerate the clinical development of the core pipeline, advance the IND application for differentiated reserve pipelines, build a new payload platform, and expand international cooperation and capitalization processes.

This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.